HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader

Shownotes are not generated by Podwise.

HCW 2026: With a $6B valuation, three approved products, up to $700M in revenue guidance this year, and a sizable acquisition under its belt, Mirum has become a rare disease leader